welcome I this extend to an progress across to warm today, Thanks for the our making Ted. to everyone another want us update we and provide are call to Thanks, of on all Tony. excited development I'm great on very joining you programs.
clinical First, level of the study I high want say commitment to investigators how I sites engagement team's programs advancing and am of despite from we clinical dedication the are how proud the COVID-XX pandemic. and our of appreciative the to ongoing our challenges trial of and
advanced with strides inhibitor monoclonal for a readouts and great candidate, important activation make the SRK-XXX our SRK-XXX which is human product and SRK-XXX, a the of to most continue highly latent both and antibody fully towards pro program. We Starting of myostatin. specific
the first muscle-directed clinically increase as promote SRK-XXX in establish to is meaningful therapy motor function for goal a potential to SMA. patients Our with
but SMA therapies we two therapies. landscape the classified distinct SMN As outlined upregulator seven, being on as therapeutic and muscle-directed treatment Slide into complementary strategies, view
of therapies, SMN prevent in Over therapies, the known past few aimed corrector which years, motor addressing as the at the are there SMN deterioration. have to order in neuron upregulator deficiency been further also development advances SMN
as at have progress, Even continue to of therapies, be disease onset for of This mean such nusinersen SMA, beyond of a in unlikely. green. Patients months category CHERISH HFMSE, needed the While the III disease of complete namely such to with from function. of to represents believe stabilize therapy, expanded baseline aim treated course. right-hand on absolute Motor in advent in important shown slide. to from manifestations as motor is driving a an the with of later for to the impairment go experienced once points motor by Functional correction appears muscle-directed we need improvement is therapeutic data Therefore, is highlighted the advances benefit invention, Scale, approach or side nusinersen function improvements of X.X Hammersmith the their primary XX shown early therapies trial individuals upregulators as SMN that Phase the second on
the the patient treated of result right-hand as Slide a motor at viewed by between SMA eight, X area. evident phenomenon compared was shown in function still scores be is clinically given gray in A with X of as look improvement this slide. that observed motor older with to even a the predominantly favorable is patient patients XX A in experience aged considered to endpoint and non-ambulatory stabilization, SUNFISH there XX, nusinersen disease. motor the of is a the this at XX% room were primarily improvements of over patients a outcome able a the young improvement, clinically deeper very treatment. Type who of In While and in occurred the depicted score different in to improvement scale, CHERISH certainly patients the is were to Type a of it and score, the Taking months The appear than usual as on use in trial as Hammersmith or initiation X treatment. course widely less of contrast, X-point XX similar in with stabilization time Hammersmith gradient MFMXX primary trial months nusinersen very five at in trial on the a for who ages risdiplam achieve significant of age. least function the function X-point meaningful meaningful, at side
was placebo, treatment and advance all disease improvement. function not upregulators point obtain primary stabilize as stabilization mean was To improvement five which met, over prevent motor neuron endpoint a significant. was which observed did across SUNFISH SMA endpoint, motor patients statistically important deterioration of phenomenon the the patients represent in in further the trial showed HFMSE in agents most not While X.XX over also this an age these the SMN X-point of reiterate, the a course. This secondary
of set SMA improvements. motor next development the for seeks the Now drive is function to era that stage drug
as potential this SRK-XXX muscle-directed trial. we now backdrop, to II turn and attention the in the has With SMA SRK-XXX our become of the to believe ongoing upregulator. SMN backbone to let's Towards any be potentially a and TOPAZ the Phase therapy that vision, first treatment
progress X. towards outlined We of SRK-XXX, therapeutic on as Slide investigating path the the potential have substantial made on
in strong investigating blockade myostatin translational have We formulated a for SMA. rationale
We preclinically Delta SMN therapeutic effect model. the X Mouse have in demonstrated
We trial and in myostatin. dosing healthy that the trial the Preliminary PD the the in data in data showed latent of TOPAZ TD evaluating regimen volunteers this are from form trial; completed the TOPAZ of a as engagement that have demonstrated target supports Phase we well. every-X-week robust SMA a patients of with that engagement adult I importantly, confirm safety; PK profile SRK-XXX, target initial
and are We on expected path efficacy look and to in forward the interim analysis quarter. the safety the fourth development along far SRK-XXX for
XX. Phase of non-ambulatory XX short, some subpopulation SMA. of before These XX treatment patients XX with patients upregulator patients X for Functional study with conjunction evaluating weeks total very age. are and distinct used the and assessments to SMA, previously aged who ages patients Turning Hammersmith of tailor the the Type expanded with X to of X outcome a ages Type initiated with every parallel with for with received Hammersmith in for SMA. non-ambulatory patients Scale, modifications clinical patients clinical X and ambulatory the trial the are approved a planned an approved older, SRK-XXX X X X for as At enrolled study SMA, review X with patients III upregulator. Phase endpoint a with Cohort Revised or designed primary the also are of either between HFMSE, patients the TOPAZ year, is RHS dosed is RHS The with or is in each Type between study and Cohort SMN II this all consists an an enrollment XX, This X Type beginning XX and Type X approved we Type XX or SRK-XXX in completed monotherapy conjunction specifically, Cohort X enrolled X SMN treated the treated patients enrolled upregulator. the SRK-XXX, of to More as X design. Slide the and of are had with Motor SMA U.S. efficacy in of Europe. X used the similar years SMA, research, efficacy to validated or SMA, TOPAZ HFMSE in evaluated IV endpoint to to Scale, nusinersen. All often in in SMN ambulatory. The and the CHERISH trial XX The served months. who and ambulatory practice a and in of the short, X and primary specifically HFMSE of be cohorts, measure
Let's for and analysis, our the interim the X-month now quarter expectations to of walk we disclose which through receive this in year. fourth expect
on efficacy with XX. and Slide Cohort readout planning looking across are X safety a We endpoints. for Starting robust
We will can improvements be rather baseline stabilization. lead treatment to from if over Hammersmith in motor merely than looking just evaluate Scale at indeed the baseline in function absolute Revised change SRK-XXX mean to
We X-point patients clinically widely individual will RHS in patient a a X-point in unexpected is meaningful. also in over of To given also be least evaluate improvement the reiterate, achieve to proportion improvement most and considered a at baseline. to be patients would
In such timed be walk addition will run, timed and also rise to from we walk test, at floor. and tests, looking and RHS, X-minute the as motor XX-meter
is While in our any impact. to that this be SMN to would will interesting the effect of base may it see assumption correction monotherapy SRK-XXX be an if SMN through have necessary patient SRK-XXX upregulator population, complement
X-point least and be looking also X, in Cohort mean proportion in individual HFMSE from retain a baseline. over of at baseline HFMSE, evaluate will we'll the the For we at improvement change patients
including of patients by of module, benefit Cohort development a be meaningful X a RULM dose the to efficacy. seeing in evaluating and on X. if initiated the in outcomes, population Health lower nusinersen limb were or upper SRK-XXX milestones. before also who still younger this in offer short, cohort enrolled dose investigate age will exploration the may Organization potential conducting World additional motor We patient revised We're
lead We in to looking see will can to be substantial treatment a a HFMSE. improvement
will of course arms, X such the differentiation effect. addition, be therapeutic between In for effect dose as potential time in therapeutic the of onset we exploring
RULM evaluated Additionally, motor patients will be and developmental WHO on milestones. the
different note SMA cohorts, us enthusiastic are the that a for in which is wider in of SMN are patients unmet cohorts subpopulation, high sizable of a a about or encourage us via approved demonstration would whether any we upregulator. broaden potential any cohorts The combination number proof-of-concept to X there X range therefore, population and of we evaluates all While and medical there would, to of these need. broader an SRK-XXX each SRK-XXX's result should X X to also subsequent investigation be the important age patients, with of of
In fiber of successful X the would validate in result addition, SRK-XXX's any hypothesis other positive Furthermore, further patients Type potential role. support motor deficits play us efficacy of investigation cohorts Cohort early a setting, X, evaluate intervention presymptomatic or disorders fast-twitch key outcome across potential the the which in therapeutic a proof-of-concept we of function and SMA in to SRK-XXX individuals. the therapeutic believe a would neuromuscular that X building as for SRK-XXX such with encourage
TOPAZ efficacy I just that to SRK-XXX, from everyone we patients want treatment to are with while the all turning active Before remind receive SRK-XXX trial, data. in firewalled the
the are We quarter. to in you fourth the and results sharing eager look forward to with see data interim the
X, extension have the As X elected the XX-month note, completed enroll who as to a final August X entire XX-month of voluntary have the patients treatment, study. all in of
cancer therapies potential our era highly which a and inhibitor response TGFßX, Now inhibitor has to believe SRK-XXX, may discuss immunotherapy. new the to of checkpoint of backbone let's selective of the we be increase
XX. Slide to Turning
treatment patients. the therapeutic revolutionized effective only a in of approach is cancers, approximately have this of of inhibitors XX% checkpoint While wide range
is XX, central what immuno-oncology response As mounting in and primary anti-PDLX in as to to the key of is in question science anti-PDX that arena culprit a TGFßX driving in the highlighted driving and So the inhibitors evidence therapy. implicates fast this on moving lack patients? most checkpoint resistance is Slide is,
fragment urothelial identified that increased the an inhibitor and levels with tumors checkpoint checkpoint an to TGFß the cells nerve say, to observation response excluded as failed around a in been survival less emerging effectively These accumulate be of to at signaling of with well TGFßX that Mechanistically, industry. in tumors well-known in tumors attention therapy outcomes example, immune association similar made but researchers into carcinoma. as reduced And Genentech tumor was excluded the is respond been to observed this therapy. tumor by captured For between the phenotype, patients to insights driving immune infiltrate lack likely inhibitor in have T to have peripheral which phenomenon. implicated has
KGaA And and PDLX. modulate Tilos commercialize and jointly bispecific Just global anti-PDLX both antibodies Merck a acquired and last molecule or Merck TGFß. GSK TGFß alliance to to develop that announced Therapeutics and develop that -- year, targets a
solid Slide As resistance of different inhibitor cancer. TGFß Earlier overcoming a towards the the XX, exhibit most in therapeutic of may a predominant types substantial year, we, proportion human delineated detailed isoform of TGFßX potential checkpoint excluded of tumors an was that phenotype. tumors. blocking immune And solid found many tumors TCGA ourselves, be broad of through the on analysis the aim publication conducted across an and this isoform that database, immunity
overcome thus, TGFßX, rates has the the increase therapeutic hypothesis emerged. has to to the checkpoint therapy potential particularly Blockade has of And approach combination now substantially inhibitor So an immunotherapy. potential exciting resistance. to this TGFß, response
Slide and SRK-XXX targeting whether latent or isoform. for several and potential Turning no through trap, may with the molecules. to its the and the ligand TGFßX offer XX. for human targeting binding nonselective of or avoiding latent to increase offers pathway. therapeutic activation antibodies fully monoclonal TGFßX Because with by a selectivity to potentially the bispecific unique through the antibody toxicities to or TGFß, SRK-XXX to TGFßX TGFßX associated of isoform, window bind to TGFß There inhibition. small are is nonselective minimal approach optimal approaches a TGFßX designed the believe latent We to SRK-XXX a
well combination given inhibitor indications of each suited the checkpoint a individual for dosage as than component enabling offer optimization enabling In linked a advantages with aptly SRK-XXX physically that having as tumor the a more of distinct a therapy. could for of may as be addition, bispecific inhibitor, over pairing be with approaches we checkpoint agent by molecule view an rather potentially anti-TGFßX
inhibition the potential the toxicity the XX. in immuno-oncology nonselective pivotal implicating against checkpoint Momentum in the robust field we with dosing significant window strong. scientific the positioned continues have to that body is of is those investigating well in multiple grow. pathway, mouse we observed for Turning preclinically, and inhibitor models. targets. pursue to for this of investigate overcome And in more to permit and TGFßX's the combination leads rationale potential TGFßX TGFß, therefore, believe a to associated the is pathway The to greater SRK-XXX exciting with TGFßX selective offers potential and role program therapy inhibition responses our of The tumor therapeutic resistance SRK-XXX SRK-XXX of is There anti-PDX a inhibition accelerating, therapeutic evidence in Slide antitumor to hypothesis.
to investigators on Phase trial dosing of the pandemic. let's the turn the in against the Now second engagement of are of encouraged I trial the the and the pace DRAGON progression, this commenced backdrop the in XX. trial Slide by We quarter trial and particularly COVID-XX
SRK-XXX will look with of the walk evaluate the the potential dose DRAGON trial. portion The the part locally Part antitumor for a expansion as significant some is trial at is anti patients in The The escalation as a B Slide tumors, will dose of therapy readouts. trialists, or activity SRK-XXX monotherapy of evaluate in comprised A anti-PDLX drew trial which trial solid or advanced enrolling the detailed clinical cords. input of of of metastatic combination safety and efficacy and and with X or trial frequent X in and Let's highlights which through thought parts. early part well the the parallel offers more A provides oncology DRAGON and design, tumor therapy. of as anti-PDX leaders XX upon with PD-LX from portion anti-PD-X combination
in AX a dose SRK-XXX escalation been trial. part have We the as of advancing agent single of
staggered therapy. AX dose evaluate AX with AX escalation to to a a this expect trial and follow AX plus of of quarter the the SRK-XXX anti-PDX initiate designed Part anti-PDLX Part trial combination or will Part in Part in progress fashion, are we design. X As to X
early the history anti-PDLX subsequently combination documented single. with a evaluating upon for is with primary addition resistance, is enrolled anti-PDX this SRK-XXX, treatment would to have to given defined of time an each to efficacy could at portion focus there illustrate, a patient potential response on lack attributed expected not While be on result of a the to response To inhibitor of a have and any of will of have safety observing course antitumor patient of If therapy. study consistent SRK-XXX. checkpoint the clinical that the SRK-XXX, or be by goes the
relatively we with observe result, could even patient a numbers. potentially signals efficacy As small
Part patients Slide This in Moving types. the combination to potential or anti-PDLX on XX. resistance enrolling parallel multiple of to to with trial of X B tumor with will across primary each checkpoint anti-PDX therapeutic SRK-XXX solid therapy inhibitors cohorts, evaluate XX DRAGON the consist to of up
across primary who non-small we who we attributable resistance with either potential for patients believe addition following nivolumab. signals lung multiple Part to this For primary we proof-of-concept we combination if of responses the to melanoma, SRK through will multiple antitumor demonstrated path treatment enroll opportunities enrolling the design for urothelial cell therapeutic And for types. cancer a with resistance effect have planning SRK-XXX, observe B carcinoma, then rapid be Again, patients and efficacy to pembrolizumab. believe pembrolizumab tumor have We or may allows be are XXX. to shown
an towards of with the registration. inhibitors, need context the high path could development Given longer-range in also checkpoint support patients primary proof-of-concept goal drug a strong resistance efficient to of unmet signal the
B pleased the are pandemic, are expeditiously. year moving of ongoing are the in update Part antitumor safety of planning in in efficacy We to with the escalation first started impacts We the trial. XXXX, Despite quarter provide this progress the COVID-XX to plan in XXXX. dose on fourth this expected an progress starting with to data we date initiate and XXXX, in and quarter
from and investigators care well all work participating staff, suffering our Before individuals Ted, to our trials. medical clinical Ted? achieving transforming Together, the as it hope I towards of as can our in I to patients turn the we I aspiration team, want and site for study thank SMA over cancer.
